Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shot up 1.8% during mid-day trading on Friday . The company traded as high as $9.40 and last traded at $9.37, with a volume of 51,521 shares. The stock had previously closed at $9.20.

A number of research firms recently issued reports on AQXP. Canaccord Genuity reissued a “buy” rating and set a $22.00 target price on shares of Aquinox Pharmaceuticals in a research note on Wednesday. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Jefferies Group increased their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, Needham & Company LLC began coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They set a “buy” rating and a $25.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $19.86.

The firm’s market capitalization is $162.48 million. The firm has a 50-day moving average of $8.25 and a 200 day moving average of $8.44.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. Equities analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.